Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14478187 | 1.00 | GRIA1 (0.50) | GRIA1GRIA3GRIA2GRIA4HTR2A | |
| SCHEMBL14945013 | 0.80 | GRIA1 (0.78) | GRIA1GRIA3GRIA2GRIA4 | |
| SCHEMBL13957545 | 0.80 | GRIA1 (0.78) | GRIA1GRIA3GRIA2GRIA4 | |
| SCHEMBL7374475 | 0.70 | HTR2A (0.41) | GRIA1GRIA3GRIA2GRIA4HTR2A | |
| SCHEMBL17000229 | 0.68 | GRIA1 (0.41) | GRIA1GRIA3GRIA2GRIA4 | |
| SCHEMBL19280767 | 0.67 | SMN1; SMN2 (0.40) | HTR2AHTR2CCA12CA1CA2 | |
| SCHEMBL4933992 | 0.67 | HTR2A (0.39) | HTR2AHTR2CCA12CA1CA2 | |
| SCHEMBL2036596 | 0.67 | GRIA1 (1.00) | GRIA1GRIA3GRIA2GRIA4 | |
| SCHEMBL2036595 | 0.67 | GRIA1 (1.00) | GRIA1GRIA3GRIA2GRIA4 | |
| SCHEMBL7167715 | 0.66 | GRIA1 (0.71) | GRIA1GRIA3GRIA2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | GRIA1 1644/4885GRIA3 1910/4885GRIA2 1898/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | GRIA1 1697/4885GRIA3 1919/4885GRIA2 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.